Original article

Polyomaviruses BK and JC DNA infection in peripheral blood cells from blood donors

Malihe Fathi Haghighi a,b, Noorossadat Seyyedi a, Ali Farhadi a, Farahnaz Zare a, Leila Kasraian c, Gholam Reza Refei Dehbidi a, Reza Ranjbaran a, Abbas Behzad-Behbahani b,a,∗

a Shiraz University of Medical Sciences, School of Paramedical Sciences, Diagnostic Laboratory Sciences and Technology Research Center, Shiraz, Iran
b Shiraz Islamic Azad University, Department of Microbiology, Shiraz, Iran
c High Institute for Research and Education in Transfusion Medicine, Blood Transfusion Research Center, Shiraz, Iran

ARTICLE INFO

Article history:
Received 4 September 2018
Accepted 16 January 2019
Available online 23 February 2019

Keywords:
Blood donors
Leukocytes
Mononuclear
Polyomavirus
Real-time polymerase chain reaction

ABSTRACT

Objectives: To investigate the prevalence of human polyomavirus (BK and JC viruses) infection in peripheral blood mononuclear cells of healthy blood donors.

Methods: The study included 250 healthy blood donors. Five-milliliter blood was drawn into sterile EDTA tubes and PBMCs were isolated from whole blood. The isolated PBMCs were counted and stored at −70 °C for future investigation. DNA was extracted and subjected to simple, sensitive and specific semi-nested PCR as well as QPCR using both general and specific primers for different assays.

Results: Of 250 blood samples, 66 (26.4%) were positive for BKV DNA (146–34,514 copies/10^6 cells), JC DNA was found in 45 (18%) blood samples (65–21,250 copies/10^6 cells). Co-infection with these viruses were found in 11 (4.4%) out of 250 blood samples.

Discussion: Our study provides important data on polyomavirus infection in peripheral blood mononuclear leukocytes in immunocompetent individuals. These data indicate significant differences between the prevalence of BKV and JCV infection in healthy blood donors. The prevalence of BK and JCV virus infection is higher in the age range 30–39 years compared to other age ranges.

© 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

∗ Corresponding author.
E-mail addresses: behzadba@sums.ac.ir, behzadba@gmail.com (A. Behzad-Behbahani).
https://doi.org/10.1016/j.bjid.2019.01.005
1413-8670/© 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

The human polyomavirus BKV and JCV are prevalent globally in populated areas but are not easily transmitted. Seroconversion to BKV infection occurs early in life (5–7 years) while to JCV occurs later. Human polyomavirus viruses, small, non-enveloped DNA, infect immunocompetent individuals without specific signs or symptoms. They are able to establish subclinical and persistent infections and may reactivate from latency in case of immunosuppression.\(^1\)\(^-\)\(^3\) Viral infection is persistent and usually established in the kidney with high levels of virus being excreted in the urine.

JCV reactivation in immunocompromised patients may cause a demyelinating disease of the central nervous system (CNS), named progressive multifocal leukoencephalopathy (PML), whereas BKV reactivation may cause hemorrhagic cystitis and polyomavirus associated nephropathy (PVAN) in renal transplant patients.\(^5\)\(^-\)\(^6\) Since no specific antiviral drugs are available to treat polyomavirus disease, treatment depends on improving immune functions to regain control over viral replication.\(^7\)

The main sanctuary of BKV and JCV persistence in healthy subjects is the kidney. However, identification of BKV and JCV DNA in peripheral blood mononuclear cells (PBMC) likely indicates recent infection by re-activation of these viruses.\(^8\)\(^-\)\(^9\) The first evidence of an interaction between BKV and hematopoietic cells was given by studies on the stimulatory effect of BKV infection on lymphocyte cultures and on BKV receptors on the surface of peripheral blood cells. These data suggested the participation of lymphoid cells in the pathogenesis of BKV infection. Nevertheless, the data on the prevalence of BKV and JCV DNA in peripheral lymphocytes is highly discordant and contradictory. Blood BKV positivity varies from 0 to 90%.\(^10\)\(^-\)\(^11\) Moreover, detection of BKV sequences in lymphocytes has disputable significance for the pathogenesis, as it is not yet clear whether these cells are persistently or transiently infected and had integrated or episomal copies of viral DNA. It is reported that 2–3% of the population have JCV in their PBMC, particularly in B-lymphocytes. However, the likelihood of secondary transmission is unknown. Overall, immunocompromised patients, pregnant women, diabetics, and the elderly appear to be at higher risk of disease and transmission of polyomaviruses.

Polyomavirus infection and viral replication have been reported in plasma and urine samples of healthy, immunocompetent blood donors. However, transmission by blood transfusion has not been documented.\(^12\) Since a number of immunocompromised transplant recipients need blood transfusion during organ transplantation procedure, the transfused blood maybe contaminated with an active form of the virus. We investigated the prevalence of polyomavirus BKV and JCV infection in healthy blood donors. Moreover, the DNA level at the time of blood donation was determined by real-time polymerase chain reaction.

Methods

Study population and the samples

A total of 250 healthy blood donors randomly selected at the blood donation center, Shiraz, Iran, were included from September through December 2017, and categorized into four age groups (20–29, n = 44, 30–39, n = 85, 40–49, n = 67, and 50–59 years, n = 54). There were only 11 females (age 19–57 years). Included donors were negative serologies for hepatitis B virus (HBV), hepatitis C virus (HCV), HIV, and Treponema pallidum infections. Participants gave written informed consent and the study was approved by the local ethics committee.

From each participant, 5 mL of blood was collected into sterile EDTA tubes at the time of regular blood donation. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque\textsuperscript{TM} (GE Healthcare, Uppsala, Sweden) gradient centrifugation (density 1.077 g/mL) and stored at −70°C for future investigation.

Semi-nested PCR

DNA extraction and PCR amplification

pBKV (34-2) plasmid (ATCC\textsuperscript{R} 45025) and pJCV (1-4) plasmid (ATCC\textsuperscript{R} 45027\textsuperscript{TM}) was used as the reference source of DNA for the PCR assays. Viral DNA from PBMCs was extracted using commercially available QIAmp DNA Blood Mini kit (Qiagen, Hilden, Germany). For the amplification of target genes, PCR was run in two separate steps, as described previously.\(^14\) The outer primers were used to amplify parts of the conserved early regions for both virus genomes. PCR amplification was carried out with 0.5–0.8 μg of extracted DNA from 1 × 10\(^6\) PBMCs, 1× PCR buffer, 1.5 mM Mg\(_2\)Cl\(_2\), 200 μM of dNTPs, 0.5 μM of each outer primer (PEP1 and PEP2), and 2.5 U of Taq DNA polymerase, in a final volume of 50 μL. The outer primer pair 5‘-AAGTCT TTA GGG TCT TCT AC-3’ and 5‘-GTG CCA ACCAT TGA ACA GA-3’ was used to amplify a 176-bp fragment common to both viruses. For specific detection, the inner primer pair combined the common primer 5‘-AAG TCT TTA GGG TCT TCT AC-3’ with either the BKV-specific primer 5‘-GAG TCC TGG TGG AGT GCC-3’ to obtain a BKV fragment of 149 bp, or the JCV specific primer 5‘-GAA TCC TGG TGG AAA ACA-3’ yielding a JCV fragment of 146 bp. Thermal cycling conditions were as follows: a first denaturing cycle at 94°C for 5 min, followed by 40 cycles of amplification defined by denaturation at 94°C for 30s, 55°C annealing temperature for 45 s, and extension at 72°C for 1 min. A final extension cycle of 72°C for 5 min was included.

In a second-round PCR, 1 μL of the 1:10-diluted first round PCR product was amplified under the above same condition with the specific inner primer pairs. The reaction was visualized on 2% agarose gel and stained with GelRed\textsuperscript{™} and visualized under UV light.

To investigate efficient DNA extraction and PCR amplification, human β-actin gene was also amplified along with the
samples using primers, which amplified a 177-bp fragment. Only positive samples were investigated further for amplification of the target DNA sequences.

SYBR green-based real-time PCR assay
A SYBR green-based real-time qPCR assay, targeting the highly conserved regions of BKV and JCV genomes, was developed for detection and quantification of BKV and JCV DNA extracted from PBMCs. Using SYBR green PCR master mix from Takara (Shiga, Japan), the optimization of the PCR reaction was performed by determining the optimal amount of primers, as well as the cycling condition. Quantitative real-time PCR was performed in a final volume of 25 μL using Qiagen Rotor-Gene Q 5-Plex (QIAGEN, Hilden, Germany). The outer forward primer 5'-AAGTCT TTA GGG TCT TCT AC-3' of semi-nested PCR (0.2 μM/reaction) with either the BKV-specific primer 5'-GAG TCC TGG TGG AGT TCC-3' or the JCV specific primer 5'-GAA TCC TGG TGG AAT ACA-3' (0.2 μM/reaction) was used for amplification in real-time PCR assay. The DNA from clinical samples was extracted as described above (Section 2.2.1) and tested (2 μL/reaction) in duplicate with the QPCR assay.

Thermal cycling was initiated with incubation at 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s, at the end of which fluorescence was read. A non-template control was included to monitor possible contamination.

Calibration curve
For the calibration curve, the threshold cycle (Ct) values were plotted against the logarithm of ten-fold serial dilutions of a plasmid containing the BKV (6 × 10^6 to 6 × 10^5 copies/reaction) and pJC (1–4) plasmid (9 × 1^6 to 9 × 1^5 copies/reaction).

Data analysis
The statistical package SPSS Version 17.0 for Windows (SPSS, Chicago, IL, USA) was used data analysis. The associations with the studied categorical variables and BKV and JCV infection were assessed using χ² test or Fisher’s exact test, when indicated.

**Results**

**Limit of detection**

The limit detection of the semi-nested PCR assay for BKV and JCV DNA was six and nine copies of plasma DNA/reaction, respectively. Serial 10-fold dilutions of pBKV and pJC were run in QPCR. Standard curves displayed a linear relationship for qPCR assay, with efficiencies of 99% for both BKV and JCV targets. Under these conditions, the limits of detection were 1–60 copies/PCR reaction for both BKV and JCV DNA. No cross-reactions were found when BKV primers were used against JCV DNA and vice versa.

**Prevalence of BKV and JCV DNA in PBMCs**

Semi-nested PCR was carried out carefully to avoid possible cross-contamination of BKV and JCV DNA. All the samples showed a positive result in the β-actin PCR, indicating absence of inhibitors and adequate amount of DNA. None of the negative controls was amplified. Results from semi-nested PCR for detection of BKV and JCV DNA in all samples are presented in Table 1. Overall, polyomaviruses BK and JC DNA were found in 111/250 PBMCs (44.4%) of healthy blood donors. BKV and JCV DNA were found in 66/250 (26.4%) and in 45/250 samples (18%), respectively. Distribution of BKV and JCV infection in various age ranges is shown in Table 1.

The overall prevalence of BKV DNA was significantly higher than that of JCV DNA in PBMCs of healthy blood donors (p = 0.03). Although the frequency of both BKV and JCV infections were higher in age range 30–39, no statistically significant differences were found related to age group (p > 0.05). Among the 11 female healthy blood donors, BKV and JCV DNA were found in PBMCs in six (54.5%) and two (18%), respectively; with co-infection in two of them. BK and JC virus DNA were not detected in blood samples of three female blood donors. On the other hand, the incidence of BKV and JCV infection in male donors were 59/239 (24.9%) and 42/239 (17.6%), respectively.

**BK and JCV DNA viral load in semi-nested PCR positive PBMCs samples**

In order to measure viral load, all semi-nested positive samples were tested by quantitative real-time PCR. Among the 66 PBMC samples positive for BKV DNA with semi-nested PCR, viral load ranged from 146 × 10^5 to 34 × 10^6 copies/10^6 PBMC by SYBR green real-time PCR. For JCV, viral load ranged from 65 × 10^5 to 21 × 10^6 copies/10^6 PBMCs. Mean viral load for BKV and JCV DNA/10^6 copies of PBMC were 5773.56 and 3652.92 with the mode of 654 and 952 respectively.

Results of QPCR for the samples with co-infection of BKV and JCV are shown in Table 2.

Descriptive statistics of BK and JCV infection in total samples are shown in Table 3.

**Discussion**

The present study shows a high frequency of BKV and JCV DNA in PBMC of healthy blood donors. Peripheral leukocytes were isolated from blood samples of healthy individuals and cellular DNA was extracted. The prevalence of BKV and JCV DNA in peripheral leukocytes from 250 healthy adult blood donors was evaluated by semi-nested PCR. The sensitivity and specificity of the method using specific inner PCR primers allow us to determine if these viruses were present in the sample tested.

In addition to the kidney, several studies have demonstrated that peripheral blood leukocytes are common sites of latent BKV and JCV infection in healthy individuals. However, persistence of BKV and JCV polyomaviruses in lymphocytes of healthy humans is still debated. The rate of PBMC infection by BKV and JCV have been reported between 0 to 90% in
Table 1 – Prevalence of BKV and JCV DNA in peripheral blood leukocytes of healthy blood donors.

| Age range (year) | Total, n (%) | BKV, n (%) | JCV, n (%) | Co-infection, n (%) |
|------------------|--------------|------------|------------|--------------------|
| 20–29            | 44 (17.6%)   | 10/44(22.7)| 7/44 (15.9)| 0                  |
| 30–39            | 85 (34%)     | 26/85 (30.6)| 21/85 (24.7)| 7 (8.2)           |
| 40–49            | 67 (26.8%)   | 16/67(23.9)| 8/67(12)  | 3(4.5)            |
| 50–59            | 54 (21.6%)   | 14/54 (30)| 9/54(16.7)| 1 (1.9)           |
| Total            | 250          | 66/250 (26.4)| 45/250 (18)| 11/250 (4.4%)    |

Table 2 – Viral load of BKV and JCV co-infected PBMCs samples.

| Donor No. | Age (year) | JCV/BKV DNA | JCV DNA copies/10^6 cells | BKV DNA copies/10^6 cells |
|-----------|------------|-------------|--------------------------|--------------------------|
| 1         | 55         | (+)         | 21,250                   | 11,876                   |
| 2         | 44         | (+)         | 4359                     | 1429                     |
| 3         | 39         | (+)         | 3580                     | 9954                     |
| 4         | 40         | (+)         | 1290                     | 2345                     |
| 5         | 36         | (+)         | 2190                     | 365                      |
| 6         | 39         | (+)         | 12,683                   | 14,900                   |
| 7         | 31         | (+)         | 876                      | 14,953                   |
| 8         | 35         | (+)         | 4912                     | 34,514                   |
| 9         | 31         | (+)         | 384                      | 12,005                   |
| 10        | 36         | (+)         | 1200                     | 654                      |
| 11        | 48         | (+)         | 948                      | 6212                     |

Table 3 – Frequency and descriptive statistics of JCV and BKV infection among positive samples.

|                | Number of positives samples | Range     | Minimum   | Maximum   | Mean     | Std. deviation |
|----------------|----------------------------|-----------|-----------|-----------|----------|----------------|
| JCV            | 44                         | 30,169.00 | 65.00     | 30,234.00| 4418.3  | 6555.3         |
| BKV            | 66                         | 34,404.00 | 146.00    | 34,550.00| 6673.1  | 9347.9         |

the various studies.10,13–17 In our investigation, the overall detection of BKV and JCV DNA in PBMC of healthy blood donors was 24.6 and 18%, respectively, which is the first report from our geographical region. In one study in China, using semi-nested PCR assay with the same primers used in our study, BKV and JCV DNA was reported in 42.1% and 7.8% of PBMC from healthy blood donors, respectively (16). Such findings indicate that BKV and JCV infection in varies in different geographic areas of the world.

Furthermore, the results of this study point out that the prevalence of BKV DNA was highly significantly higher compared to that of JCV DNA (p = 0.03). Because of the small sample of female blood donors (11/250 donors) the impact of sex on the results could not be ascertained, BK virus infection seemed to be more common than JCV virus infection (3:1). Although the prevalence of BKV and JCV DNA in PBMC was higher in the age range 30–39 years, there was no statistically significant difference among age groups.

BK polyomavirus is associated with nephropathy and ureteric stenosis in kidney transplant recipients as well in other types of transplant recipients.18,19 BKV causes hemorrhagic cystitis in allogenic hematopoietic cell transplant recipients.20 However, less than 5% of polyomavirus nephropathy among kidney transplant recipients may be caused by JC, perhaps with more inflammation and focal fibrosis, and is typically associated with a milder clinical course.21

Generally, primary infection of BKV and JCV in healthy individuals is followed by lifelong viral persistence. Both of these viruses are shed in the urine of healthy people. However, immunosuppression may reactivate latent virus in healthy individuals and cause disease.

Real-time quantitative PCR was used to quantitate DNA of polyomaviruses BK (BKV) and JC (JCV) in PBMCs of healthy individuals. There is no standard level of polyomavirus DNA in healthy or even in patients. Many variables including sample processing protocol and sensitivity and specificity of detection methods may affect the ultimate results of quantitative PCR assays. Environmental factors such as age, sex, personal hygiene, individual’s immune status can interfere with the result of the assay. Based on the findings of this study, the virus persists in blood mononuclear leukocytes in up to 25% of healthy blood donors who are lifelong carriers of the virus. It can be transmitted by transfusion of cellular blood components although this may be difficult to distinguish from reactivation of a previous infection. BKV infection, in particular, can cause severe infection in renal transplant and immunocompromised individuals. Therefore, polyomavirus
disease transmitted through PBMCs during blood transfusion should not be neglected.

We have shown that BKV and JCV can infect PBMCs of healthy individuals and establish a latent infection. In our experiment, the DNA level in different individuals varies from $146 \times 10^5$ to $34 \times 10^3$ copies/10^6 PBMC for BKV and $65 \times 10^5$ to $21 \times 10^3$ copies/10^6 PBMC for JCV DNA. Therefore, when transfusing blood to an immunosuppressed patient transmission of the high level of infected cells with polyomavirus may result in severe disease.

In conclusion, our study provides important data on polyomavirus infection in peripheral blood mononuclear leukocytes in immunocompetent individuals living in the southwest of Iran. These data indicate significant differences between the prevalence of BKV and JCV infection in healthy blood donors. The prevalence of BK and JC virus infection is higher in the age range 30–39 years compared to other age ranges. Different levels of BK and JC virus DNA was found in PBMCs of healthy blood donors. However, viral DNA quantitation in plasma samples by real-time PCR helps identifying ongoing viral reactivation.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Conflicts of interest**

The authors declare no conflicts of interest.

**Acknowledgments**

This research was supported by Shiraz University of Medical Sciences Grant Number 97-01-45-17407.

**References**

1. Khalili K, Stoner GL. Human polyomaviruses: molecular and clinical perspectives. John Wiley & Sons; 2004.
2. Arthur RR, Dagostin S, Shah KV. Detection of BK virus and JC virus in urine and brain tissue by the polymerase chain reaction. J Clin Microbiol. 1989;27:1174–9.
3. Butel JS, Lednicky JA. Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst. 1999;91:119–34.
4. Lednicky JA, Arrington AS, Stewart AR, et al. Natural isolates of simian virus 40 from immunocompromised monkeys display extensive genetic heterogeneity: new implications for polyomavirus disease. J Virol. 1998;72:3980–90.
5. Weber T, Major EO. Progressive multifocal leukoencephalopathy: molecular biology, pathogenesis and clinical impact. Intervirology. 1997;40:98–111.
6. Celik B, Randhawa PS. Glomerular changes in BK virus nephropathy. Hum Pathol. 2004;35:367–70.
7. Rinaldo CH, Hirsch HH. Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti-Infect Ther. 2007;5:105–15.
8. Barbanti-Brodano G, Martini F, De Mattei M, Lazzarin L, Corallini A, Tognon M. BK and JC human polyomaviruses and simian virus 40: natural history of infection in humans, experimental oncogenicity, and association with human tumors. Adv Virus Res. 1998;50:69–99.
9. Boldorini R, Caldarelli-Stefano R, Monga G, et al. PCR detection of JC virus DNA in the brain tissue of a 9-year-old child with pleomorphic xanthoastrocytoma. J Neurovirol. 1998;4:242–5.
10. Dolei A, Pietropaolo V, Gomes E, et al. Polyomavirus persistence in lymphocytes: prevalence in lymphocytes from blood donors and healthy personnel of a blood transfusion centre. J Gen Virol. 2000;81:1967–73.
11. Dörries K, Vogel E, Günther S, Czub S. Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals. Virology. 1994;198:59–70.
12. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis. 2009;199:837–46.
13. Nickeleit V, Hirsch HH, Binet IF, et al. Polyomavirus infection of renal allograft recipients from latent infection to manifest disease. J Am Soc Nephrol. 1999;10:1080–9.
14. Tornatore C, Berger JR, Houff SA, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol. 1992;31:454–62.
15. Sundsfjord A, Flågstad T, Flå R, et al. BK and JC viruses in human immunodeficiency virus type 1-infected persons: prevalence, excretion, viremia, and viral regulatory regions. J Infect Dis. 1994;169:485–90.
16. Azzi A, De Santis R, Ciappi S, et al. Human polyomaviruses DNA detection in peripheral blood leukocytes from immunocompetent and immunocompromised individuals. J Neurovirol. 1996;2:411–6.
17. Gu ZY, Li Q, Si YL, Li X, Hao HJ, Song HJ. Prevalence of BK virus and JC virus in peripheral blood leukocytes and normal arterial walls in healthy individuals in China. J Med Virol. 2003;70:600–5.
18. Egli A, Helmersen DS, Taub K, et al. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. Am J Transplant. 2010;10:2324.
19. Hirsch HH, Randhawa P, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:179.
20. Arthur RR, Shah KV, Baust SJ, et al. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med. 1986;315:230.
21. Hirsch HH, Randhawa P, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:179.